|
Indication |
Active immunity against vaccinia and smallpox |
|
Proprietary Name |
Dryvax |
|
Manufacturer |
Wyeth |
|
Viability |
Live attenuated |
|
Microorganism |
Double-stranded DNA vaccinia virus genus
orthopoxvirus |
|
Dose |
2 to 3 pressures or punctures |
|
Route |
Percutaneous using bifurcated needle |
|
Dose form |
Powder for suspension |
|
Appearance |
Glossy and cloudy suspension |
|
Concentration |
|
|
Full-strength |
108 pock-forming units/mL |
|
Administered dose |
2.5 x 105 pock-forming units |
|
Preservatives |
Phenol 0.25% |
|
Adjuvant |
None |
|
Excipients |
Brilliant green diluent until the 1980’s. Since
2002 diluent no longer brilliant green |
|
Allergens |
Calf lymph,
Polymyxin B,
100 units/mL
Dihydrostreptomycin,
200 mcg/mL
Chlortetracyclin,
200 mcg/mL
Neomycin, 100 mcg/mL |
|
Media |
Skin of vaccinated bovine calves |
|
Packaging |
Vial and Diluent for 100 vaccinations |
|
Routine Storage |
2 to 8°
C
Shipped at 0°
C or cooler |
|
updated July 2005 |